PW
Walker, Paul Richard
Affiliation entities
Research groups
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade | Cellular and molecular life sciences | 2025 | 16 | 8 | |||
PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | 2024 | 205 | 172 | |||
Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro | Radiotherapy and oncology | 2024 | 66 | 12 | |||
Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming | International journal of molecular sciences | 2024 | 56 | 28 | |||
Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages | Cell communication and signaling | 2024 | 78 | 17 | |||
Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy | Clinical and Experimental Medicine | 2024 | 44 | 23 | |||
How to outsmart the cold tumor microenvironment: Design of STING ligand nanoparticles for improved cancer immunotherapy | OpenNano | 2023 | 35 | 11 | |||
Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | 2023 | 266 | 57 | |||
Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition | Neuro-oncology | 2022 | 259 | 100 | |||
Synthesis, Formulation and Characterization of Immunotherapeutic Glycosylated Dendrimer/cGAMP Complexes for CD206 Targeted Delivery to M2 Macrophages in Cold Tumors | Pharmaceutics | 2022 | 214 | 63 | |||
An update on actively targeted liposomes in advanced drug delivery to glioma | International journal of pharmaceutics | 2021 | 138 | 1 | |||
Glioma-Derived Extracellular Vesicles - Far More Than Local Mediators | Frontiers in immunology | 2021 | 179 | 92 | |||
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma | Journal for immunotherapy of cancer | 2021 | 229 | 108 | |||
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) | JCI insight | 2021 | 216 | 56 | |||
Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells | Communications Biology | 2021 | 299 | 182 | |||
An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | 2020 | 435 | 265 | |||
Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer | Journal of Controlled Release | 2020 | 233 | 132 | |||
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review | Journal for immunotherapy of cancer | 2020 | 157 | 160 | |||
Harnessing Microglia and Macrophages for the Treatment of Glioblastoma | Frontiers in Pharmacology | 2019 | 417 | 229 | |||
Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine | JCI Insight | 2019 | 269 | 3 | |||
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | 2019 | 764 | 385 | |||
Peptides as cancer vaccines | Current Opinion in Pharmacology | 2019 | 385 | 4 | |||
Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models | OncoImmunology | 2018 | 380 | 1 | |||
Let there be oxygen and T cells | Journal of Clinical Investigation | 2018 | 360 | 155 | |||
Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines | Cellular and Molecular Life Sciences | 2018 | 362 | 150 | |||
Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | 2018 | 628 | 277 | |||
Immunothérapie des gliomes : illusion ou espoir ? | Bulletin du cancer | 2017 | 384 | 0 | |||
Identification of a novel population of highly cytotoxic c-Met-expressing CD8(+) T lymphocytes | EMBO Reports | 2017 | 552 | 4 | |||
ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells | EMBO Journal | 2017 | 572 | 10 | |||
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Frontiers in Oncology | 2016 | 482 | 392 | |||
Cell-penetrating peptides-the Swiss Army knife of cancer vaccines | Oncoimmunology | 2016 | 599 | 271 | |||
Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes | PloS one | 2016 | 539 | 202 | |||
Hypoxia and antitumor CD8(+) T cells: An incompatible alliance? | OncoImmunology | 2016 | 452 | 262 | |||
Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing | PloS one | 2016 | 569 | 598 | |||
Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants | Molecular therapy | 2016 | 630 | 288 | |||
Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells | European Journal of Immunology | 2015 | 514 | 7 | |||
Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity | Cancer research | 2015 | 587 | 10 | |||
Immunotherapy of Brain Tumors | Progress in tumor research | 2015 | 545 | 0 | |||
The CD40/CD40L axis in glioma progression and therapy | Neuro-oncology | 2015 | 463 | 169 | |||
Immunotherapy for glioma: from illusion to realistic prospects? | American Society of Clinical Oncology educational book | 2014 | 1,229 | 573 | |||
Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours | PloS one | 2013 | 671 | 305 | |||
The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity | Journal of neuroinflammation | 2013 | 599 | 336 | |||
Getting by with a little help from the right CD4+ T cells | Oncoimmunology | 2013 | 531 | 210 | |||
Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies | Immunotherapy | 2013 | 505 | 0 | |||
Macrophages and Microglia in Brain Malignancies | Tumor Microenvironment and Myelomonocytic Cells | 2012 | 500 | 587 | |||
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy | Brain | 2012 | 650 | 1,292 | |||
Oncology ESAB 2011 | 2011 | 622 | 10 | ||||
Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development | Cancer research | 2010 | 581 | 3 | |||
T-cell immunotherapy for malignant glioma: toward a combined approach | Current opinion in oncology | 2010 | 634 | 2 | |||
Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes | GLIA | 2008 | 608 | 11 |